Looking for Fingerprints: Bioanalytical Characterization of Biosimilars - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Looking for Fingerprints: Bioanalytical Characterization of Biosimilars
Extensive physicochemical characterization of the innovator product and the proposed biosimilar provides the foundation for demonstrating biosimilarity.


Pharmaceutical Technology
Volume 36, Issue 6, pp. 36-41

More difficult than it appears

Although copying an innovator's product may appear easier than developing a novel therapeutic, the difficulties of engineering one product to match an existing product cannot be underestimated. Rudd points out that it is considerably more difficult to produce a biosimilar product than simply inserting a DNA construct into a cell line and expecting that the innovator product will be faithfully reproduced. For biologics, the process is intimately connected with the disposition of the final product, but the biosimilar manufacturer does not have knowledge of the processes used by the innovator.

Xu points out, however, that manufacturers have better understanding of and more control over processes than they did 20 years ago. Implementation of process analytical technology and use of quality-by-design principles in setting up the process will greatly facilitate production of a consistent product. For any biosimilar, he recommends engaging the analytical team early in the process so that the developer can determine how process changes will affect critical quality attributes. In some instances, there may be correlations between process parameters and protein structural attributes, allowing the protein attributes to be fine-tuned.

EMA is well ahead of the US in biosimilars development, having approved its first biosimilar in 2006, and with 14 biosimilar products now on the market. EMA has already released guidance documents that are specific for different product types, including epoetins, filgastrims, and a draft guidance for monoclonal antibodies (8–10). Such product-specific specifications will doubtless be released by FDA in time, and will help better define what a fingerprint looks like.

References

1. FDA, Draft Guidance, Scientific Considerations in Demonstrating Bioimilarity to a Reference Product (Rockville, MD, February 2012).

2. FDA, Draft Guidance, Quality Considerations in Demonstrating Bioimilarity to a Reference Product (Rockville, MD, February 2012).

3. FDA, Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009 (Rockville, MD, February 2012).

4. FDA, Generic Enoxaparin Questions and Answers, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220037.htm, accessed May 2012.

5. ICH, Q6B Specifications: Test Procedures and Acceptance Criteria for. Biotechnological/Biological Products (1999).

6. P. Hossler, SF Khattak, and ZJ Li, Glycobiol. 19 (9), 936–949 (2009).

7. D. Fernandes, BioPharm Intl. 24 (1) (2011).

8. EMA, Guidance on Similar Medicinal Products Containing Recombinant Erythropoietins (Sept. 2010).

9 . EMA, Guidance on Biosimilar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor (June 2006).

10. EMA, Draft Guideline, Similar Biological Medicinal Products Containing Monoclonal Antibodies (Sept. 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here